Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference

IDrugs. 2006 Mar;9(3):179-81.
No abstract available

Publication types

  • Congress

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Apoptosis / drug effects
  • Boronic Acids / pharmacology
  • Boronic Acids / therapeutic use
  • Bortezomib
  • Cell Proliferation / drug effects
  • Clinical Trials as Topic
  • Deubiquitinating Enzyme CYLD
  • Humans
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / metabolism
  • Protease Inhibitors / pharmacology
  • Protease Inhibitors / therapeutic use
  • Proteasome Endopeptidase Complex / metabolism
  • Proteasome Inhibitors*
  • Pyrazines / pharmacology
  • Pyrazines / therapeutic use
  • Signal Transduction / drug effects
  • Tumor Suppressor Proteins / metabolism
  • Ubiquitin / metabolism*
  • Ubiquitin-Protein Ligases / metabolism
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Protease Inhibitors
  • Proteasome Inhibitors
  • Pyrazines
  • Tumor Suppressor Proteins
  • Ubiquitin
  • Bortezomib
  • Ubiquitin-Protein Ligases
  • CYLD protein, human
  • Deubiquitinating Enzyme CYLD
  • Proteasome Endopeptidase Complex